Report of the 7th virtual end TB strategy summit for the highest TB burden countries and countries on the WHO global watchlist, 16–17 November 2021

Report of the 7th virtual end TB strategy summit for the highest TB burden countries and countries on the WHO global watchlist, 16–17 November 2021 WHO End TB Strategy Summit Report of the 7th virtual end TB strategy summit for the highest TB burden countries and countries on the WHO global watchlist, 16–17 November 2021 ISBN 978-92-4-004693-1 (electronic version) ISBN 978-92-4-004694-8 (print version) © World Health Organization 2022 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. Report of the 7th virtual end TB strategy summit for the highest TB burden countries and countries on the WHO global watchlist, 16–17 November 2021. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third- party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. This publication contains the report of the 7th virtual end TB strategy summit and does not necessarily represent the decisions or policies of WHO. i Contents Abbreviations ................................................................................................................................................ i Introduction .................................................................................................................................................. 1 1. The impact of the COVID-19 pandemic on reaching the Global TB Targets (Session 1) ................... 2 2. Pillar 1 – Integrated people centered care and prevention in the time of the COVID-19 pandemic (Session 2) ............................................................................................................................................ 4 3. Pillar 2 – Bold polices and supportive systems to End TB in the context of the COVID-19 pandemic (Session 3) ............................................................................................................................................ 6 4. Pillar 3 – Intensified research and innovation and learning lessons from the COVID-19 response (Session 4) ............................................................................................................................................ 8 5. Looking ahead - Key Updates (Session 5) ........................................................................................... 9 6. Closing ................................................................................................................................................ 10 Annex 1: Agenda for the Summit’s AM and PM session .......................................................................... 12 Annex 2: List of participants ...................................................................................................................... 23 Abbreviations AFR WHO African Region AMR WHO Region of the Americas CSTF Civil Society Task Force EMR WHO Eastern Mediterranean Region EUR WHO European Region MAF-TB Multisectoral Accountability Framework for TB NTP National TB Programme SEAR WHO South-East Asia Region TB Tuberculosis The Global Fund The Global Fund to Fight AIDS, Tuberculosis and Malaria UHC Universal Health Coverage UN United Nations UNHLM UN high-level meeting USAID United States Agency for International Development WHO World Health Organization WPR WHO Western Pacific Region 1 Introduction The World Health Organization (WHO), through its Global Tuberculosis (TB) Programme, leads and guides the global effort to end the TB epidemic through universal access to people-centred prevention and care, multisectoral action and innovation. The major functions of the Global TB Programme include: • providing global leadership to end TB through strategy development, political and multisectoral engagement, strengthening of reviews and accountability, and advocacy and partnerships (including with civil society); • developing policy options, norms and standards of TB prevention and care, and facilitating their implementation; • shaping the TB research and innovation agenda, and stimulating the generation, translation and dissemination of knowledge; • providing specialized technical support for Member States and partners, and working with WHO regional and country offices to catalyse change and build sustainable capacity; and • monitoring, evaluating and reporting on the status of the TB epidemic and progress in the financing and implementation of the End TB Strategy. The 7th End TB summit of the highest TB burden countries and countries on the WHO Global TB Watchlist took place virtually from 16 to 17 November 2021 (3.5 hours per day). The overall objective of this summit was to facilitate discussions and an exchange of strategic information between National TB Programmes (NTPs), representatives of the WHO Civil Society Task Force, and partners on new ways of working to mitigate and reverse the COVID-19 impact on TB and reinvigorate the global response to TB. Specific meeting objectives were as follows: 1. to reflect on key challenges and opportunities posted by the ongoing COVID-19 pandemic for NTPs, affected people and vulnerable populations; 2. to consider opportunities for strengthening quality TB case finding and prevention given innovations during the COVID-19 pandemic; 3. to share updates on the latest global situation for TB and exchange strategic information. As participants were based in different time zones, two virtual sessions of the summit were held: • 09:00 to 12:30 CET: including countries from the WHO Eastern Mediterranean Region (EMR), the WHO European Region (EUR), the WHO South-East Asia Region (SEAR), and the WHO Western Pacific Region (WPR); • 14:00 to 17:30 CET: including countries from the WHO African Region (AFR) and the WHO Region of the Americas (AMR). The working language for the summit was English. Simultaneous interpretation in French, Portuguese, Russian, and Spanish was made available via the webinar platform. Agendas for both segments of the summit included 5 major sessions, 3 of which were focused on the 3 pillars of the End TB Strategy (Annex 1): 1. The impact of the COVID-19 pandemic on reaching the Global TB Targets; 2. Pillar 1 – Integrated people centered care and prevention in the time of COVID-19; 3. Pillar 2 – Bold policies and supportive systems to End TB in the context of the COVID-19 pandemic; 4. Pillar 3 – Intensified research and innovation, lessons learnt from the COVID-19 response; and 5. Looking ahead and key updates. 2 These were followed by a closing session. The meeting was attended by over 350 participants (Annex 2). This report summarizes the sessions of the summit and provides links to background slides shared by speakers from the country, regional and global level. All slides are featured in the WHO End TB Forum. To access documents (and links shared in this report) registration1is needed. 1. The impact of the COVID-19 pandemic on reaching the Global TB Targets (Session 1) Session 1 was an informative session. It was opened by Dr Tereza Kasaeva, Director of WHO’s Global TB Programme, providing reflections on the impact of the COVID-19 pandemic and actions needed to restore and scale-up TB activities to reach Global TB targets. Next, Dr Katherine Floyd from WHO’s Global TB Programme provided an update on key findings and messages from the 2021 Global TB Report. The following partners then proceeded to share their perspectives: Dr Lucica Ditiu, Director of the Stop TB Partnership; Dr Eliud Wandwalo and Dr Mohammed Yassin from The Global Fund to Fight AIDS Tuberculosis and Malaria (The Global Fund), and Dr YaDiul Mukadi from the United States Agency for International Development (USAID). The session was concluded by observations from the WHO’s Civil Society Task Force, represented by Ms Blessi Kumar and Professor Harry Hausler. Further detail is provided below. • Dr Tereza Kasaeva reflected on the current global TB situation, key issues and lessons learnt during the COVID-19 pandemic and resulting identified priorities, targets and commitments made by Member States at the 2018 United Nations (UN) high-level meeting (UNHLM) on tuberculosis, opportunities for innovative action, the need to ensure rapid uptake of new TB guidelines, and advantages of using digital technologies, and data and surveillance for informed decision making. The need to continue efforts regarding the uptake of the multisectoral accountability framework for TB (MAF-TB), advocacy efforts aimed at elevating TB to a priority intervention at country level amid the COVID-19 pandemic, the mobilization of additional resource for TB was emphasized. WHO’s continued role in providing global leadership for the TB response and WHO’s close engagement and collaboration with all stakeholders, in particular in the lead-up to the 2023 UNHLM on TB, was also reconfirmed. Link to slides presented by Dr Tereza Kasaeva (WHO)2 • Dr Katherine Floyd provided an update on key findings and messages of the 2021 Global Tuberculosis Report.3 The following 2 overarching findings were spotlighted: The COVID-19 pandemic has reversed years of progress in providing essential TB services and reducing TB disease burden; and global TB targets being mostly off track, despite there being some country and regional success stories. The following impacts of the COVID-19 pandemic were also highlighted: (1) a large global drop in the number of people newly diagnosed with TB and reported (i.e. 7.1 million in 2019 to 5.8 million in 2020); (2) an increase in TB deaths due to reduced access to TB diagnosis and treatment; and (3) declines in TB incidence (the number of people developing TB each year) achieved in previous years having slowed almost to a halt. It was further confirmed that these impacts are forecasted to be much worse in 2021 and 2022. Other effects emphasized by Dr Floyd included the observed reductions between 2019 and 2020 in the number of people provided with treatment for drug-resistant TB (-15%, from 177 100 to 150 359, about 1 in 3 of those in need) and TB preventive treatment (-21%, from 3.6 million to 2.8 million), and a fall in global spending on TB diagnostic, 1 https://global-tb-programme.hivebrite.com/signup 2 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/78ab9a24-b029-4c80-b8b0-72386e0f246f 3 https://www.who.int/publications/i/item/9789240037021 3 treatment and prevention services (from US$ 5.8 billion to US$ 5.3 billion, less than half of what is needed). Participants were reminded of the need for urgent action to mitigate and reverse the impact of the COVID-19 pandemic and the urgency to restore access and provision of essential TB services such that the levels of TB case detection and treatment can recover to at least 2019 levels. Participants were invited to use the WHO developed mobile application to access regional and global data for all key indicators. Link to slides presented by Dr Katherine Floyd (WHO).4 • Dr Lucica Ditiu, from the Stop TB Partnership, stressed the need for all actors to be committed to ending TB, albeit the challenging context due to the COVID-19 pandemic. Participants were urged to (1) avail and implement country specific strategic plans in which planned interventions are prioritized and focused on restoring and scaling-up access to essential TB services; (2) be ready to absorb resources made available by governments and partners to facilitate progress towards global targets and the mobilization of additional resources for TB; and (3) ensure active and strategic engagement of multiple actors in the response to TB, in particular civil society organizations, communities affected by TB and the private sector. Participants were also reminded of existing opportunities to learn from and integrate COVID-19 and TB response strategies and the importance of considering other risk factors, such as malnutrition, to ensure comprehensive response to TB. • The Global Fund, represented during the summit by both Dr Eliud Wandwalo (AM session) and Dr Mohammed Yassin (PM session), confirmed the need for innovative action, an out-of-the-box, campaign style approach to ensure rapid catch-up and scale-up of TB interventions needed to meet global targets and end TB by 2030. A critical factor to the mobilization of additional resources for TB was identified by speakers as being countries’ ability to demonstrate the capacity to absorb fully the available Global Fund resources. • Dr YaDiul Mukadi, from the United States Agency for international Development (USAID), reflected on the need to collect data on the long-term impact on patients suffering from COVID-19 and TB (either simultaneously or subsequently) to inform interventions going forward. The need to ensure access to high quality, real time data for strategic decision making was also emphasized. The importance of scaling-up innovative interventions (esp. use of digital technologies) and further exploring how TB can benefit from actions introduced at country level in response to the COVID-19 pandemic was highlighted. Given expected economic constraints due to the COVID-19 pandemic, Dr YaDiul Mukadi closed by re-emphasizing the need for innovative action to increase case notification. In this regard the use of data generated by social media for the scale-up of TB interventions was noted. • The WHO Civil Society Task Force on TB, represented during the summit by Ms Blessi Kumar (AM session) and Professor Harry Hausler (PM session) invited NTPs and WHO Country Offices to renew efforts to ensure a meaningful engagement of civil society and community actors to accelerate the response to TB at country, regional and global level. The need to safeguard, champion and sustain joint actions was emphasized, in particular regarding the uptake of the MAF-TB, the development of guidelines and tools at country level, implementation of the community treatment observatory model, and community-led monitoring. Examples of good practices were shared with participants. Links to slides presented by Ms Blessi Kumar (AM session)5 and Professor Harry Hausler (PM session)6 from the WHO Civil Society Task Force. 4 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/8061497b-0156-408b-866f-6a88d0b8a6c5 5 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/c74e0290-06de-4793-9c18-b39113aa5788 6 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/3f2f5abe-da8f-4397-b453-ea2138538173 4 2. Pillar 1 – Integrated people centered care and prevention in the time of the COVID-19 pandemic (Session 2) Session 2 was an interactive session, moderated by Ms Hannah Monica Dias (WHO), that aimed to create awareness of the status of implementation of pillar 1 in all six WHO regions and to facilitate sharing of country experiences and best practices on the following 6 topics: (1) TB prevention and screening; (2) TB diagnosis; (3) TB treatment; (4) public-private mix (PPM); (5) comorbidities and vulnerable populations; and (6) community and civil society engagement. To achieve the above-referenced objectives, the session was divided into 2 main segments: 1. A panel discussion and an open poll: Panel discussions were stratified 2 ways, i.e. by region, and with a spotlight on country experiences vis- a- vis the above-referenced six topics. In parallel, the audience was invited to post their experiences on the above-referenced topic areas via an open poll. Outcomes were presented by the moderator and highlights identified. The presenters of selected highlights were given the opportunity to elaborate on shared statements. 2. An interactive forum on key priorities and interventions to enable rapid implementation of pillar 1: Using an open poll, participants were invited to express their perceived priorities and innovations to facilitate implementation of pillar 1. Findings were presented to the audience at the end of the session. Links to background information made available by presenters are captured in tables 1 and 2 below. Table 1: Links to background information presented by WHO TB Regional Advisors Name of Presenter Link to slides Dr André Ndongosieme AFRO7 Dr Rafael Lopez Olarte AMRO/PAHO8 Dr Martin van den Boom EMRO9 Dr Askar Yedilbayev EURO10 Dr Mukta Sharma SEARO11 Dr Tauhid Islam WPRO12 Table 2: Links to country spotlights presented during the panel discussion Thematic Area Focus of intervention Link to slides TB prevention and screening TB case finding strategy in Zambia Dr Patrick Saili Lungu, NTP Manager, Zambia Zambia13 TB preventive reatment and Systematic Screening for TB in the Republic of Kazakhstan Dr Adenov Malik Moldabekovich, Director of the National Scientific Center of Phthisiopulmonology of the Ministry of Health of the Republic of Kazakhstan Republic of Kazakhstan14 7 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/6cf16008-9415-452a-af0a-94b554e20322 8 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/54e65455-b758-4d7c-8e0a-582679fc3625 9 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/2eb20479-bfd8-4955-b3e6-78d5c9f0ba45 10 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/3c9dd53f-8914-4467-b497-794a361f68dd 11 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/4b30fbe8-53ab-416f-92aa-d40408114f76 12https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/47c8d3ae-210f-4f6d-b955-7bde39d42410 13 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/903d6894-6e22-4277-9b97-8f59fbb8cfd5 14 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/ddb81283-187a-47c8-86d1-0eb6d4e13826 5 TB diagnosis Experience of Uganda in using Xpert MTB/RIF assay as an initial test for TB diagnosis Dr Stavia Turyahabwe, Programme Manager, NTP Uganda Uganda15 Progress made in the Philippines concerning the use of WHO-recommended rapid diagnostic tests Dr Anna Marie Celina Garfin, Medical Specialist IV, NTP manager, Philippines Philippines16 TB treatment Experience in transitioning to the new shorter rifampicin- resistant TB regimens in South Africa Dr Norbert Ndjeka, Director of DR-TB, National Department of Health, South Africa South Africa17 Strategy adopted by Ukraine vis-à-vis the uptake of WHO guidance on drug-resistant TB treatment Dr Yana Terleieva, Head of TB Diagnosis and Treatment Coordination, Department, Public Health Center of the Ministry of Health of Ukraine Ukraine18 Public- Private Mix (PPM) Innovative approaches used in Nigeria to strengthen the engagement of the private or unengaged public health care providers Dr Chukwuma Anyaike, Director and National Coordinator, NTP, Nigeria Nigeria19 Involving private and unengaged public sector health care providers in India to ensure access to quality TB prevention and care Dr Sudarsan Mandal, Deputy Director General TB, NTP, India India20 Comorbidities and vulnerable populations Experience of managing diabetes mellitus and TB in Peru Dr Julia Rosa María Rios Vidal, NTP manager, Peru Peru21 Pakistan’s experience in managing childhood and adolescent TB, TB and HIV, and TB and diabetes mellitus Dr Basharat Javed, Common Management Unit for AIDS, TB, and Malaria, Pakistan Pakistan22 Community and civil society engagement: Experience of civil society engagement in the TB response in Kenya amidst the COVD-19 pandemic Ms Evaline Kibuchi, WHO Civil Society Task Force member, Kenya Kenya23 Reflections from civil society perspective on actions needed on pillar 1 in the lead-up to the UNLHM 2023 Dr Esty Febriani, Civil Society Task Force member, Indonesia Speaker did not present slides. 15 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/447620a3-8d65-484a-ab7e-d105791573f3 16 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/4ae0ad30-c156-46c5-b4ec-3901408e6ece 17 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/ab0689e8-593e-4379-b98a-47b231840b1b 18 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/5be7c1e7-cb2a-4a14-9e02-eb7b34d764e9 19 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/36bc4c26-dcc4-41fe-ac47-b082f4bb2a86 20 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/29802d5e-1d9a-4af9-b5d1-430a08a3c248 21 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/6e6bdbe0-ebac-431f-9305-66f2658279a6 22 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/95993db5-5e1b-47c9-848d-54bb50703e6b 23 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/04e2d653-fa6a-4d68-b610-cad1e66eb4f5 6 Top 10 priorities and innovations to enable rapid implementation of Pillar 1, as identified by participants through the open poll are featured below (please note that actions are not ranked by order of priority). Outcomes of poll involving participants from EMR, EUR, SEAR, and WPR: 1. Vaccine development; 2. Universal roll-out of rapid molecular diagnostics (Xpert, Truenat) as the initial diagnostics test for all people with presumptive TB (at all levels of care); 3. Active TB case finding in nationally defined high-risk groups; 4. TB preventive treatment: Access and affordability of diagnostics and medicines for prevention and treatment; capacity building of affected communities; 5. MAF-TB and primary health care strengthening; 6. Involvement of NGOs in screening activities in hard-to-reach populations; 7. Rapid uptake of WHO guidelines on the use of shorter regimens and participation in operational research activities; 8. Application based TB self-diagnosis, treatment, and follow-up; 9. Use of digital technical technologies: use of artificial intelligence for chest X-ray reading in the event of active case findings from TB preventive treatment; and 10. Youth engagement. Outcomes of poll involving participants from AFR and AMR: 1. Civil society and community engagement to reach vulnerable populations; 2. Targeted, universal TB testing of high-risk groups; 3. Inclusion of non-public sector health facilities in TB screening activities and their connection to the sample referral system; 4. Use of rapid molecular diagnostics (Xpert, Truenat) as the initial diagnostic test; 5. Use of digital screening tools (including use of artificial intelligence); 6. Intensified case finding among vulnerable populations (e.g. through mobile clinics; innovative initiatives such as the use of riders, the Kick TB initiative in Kenya, etc.); 7. TB preventive treatment: Adoption of 3HP regimen and contact investigation; 8. Development of national guidelines for joint interventions on TB and COVD-19; 9. Training, regular performance analysis with feedback; and 10. Electric power back-up; service and maintenance for instruments. 3. Pillar 2 – Bold polices and supportive systems to End TB in the context of the COVID-19 pandemic (Session 3) Session 3 was an interactive session, aiming to discuss and share experiences between countries, with a focus on the following 2 topics: the operationalization of multisectoral accountability framework, and how to leverage social protection for people affected by TB in time of COVID-19 (with a spotlight on experiences of member states and TB stakeholders). Both session segments included a live question and answer session. Operationalization of multisectoral accountability framework for TB (MAF-TB) The session was moderated by Dr Sayohat Hasanova (WHO), Dr Martin van den Boom (WHO), and Dr Rafael Lopez (WHO/PAHO). In the introductory part of the session, the need for multisectoral accountability to address social determinants of the TB epidemic was reconfirmed. Overarching findings from 7 assessments conducted by Member States using the WHO developed MAF-TB checklist highlighted the progress in the adaptation and use of MAF-TB framework at global, regional, and country level, i.e. • progress in adaptation and implementation of the MAF-TB is being made; • areas requiring strengthening include: (i) the engagement of all relevant sectors including civil society; (ii) mechanisms for high level review. These findings were contextualized for the 6 WHO regions. Given the impact of the COVID-19 pandemic MAF-TB was also highlighted as a key tool to help recovery of essential TB services, enhanced social protection and faster progress towards global TB targets. Thereafter country and regional experience in implementing MAF-TB were highlighted. Link to slides presented by Dr Sayohat Hasanova24 in the afternoon session of the summit. Links to slides made available by speakers are captured in the below table. Table 3: Links to country and regional experience on MAF-TB Focus of intervention Link to slides Multisectoral agenda for the TB response and review mechanisms: the Brazilian experience Dr Tiemi Arakawa, NTP, Brazil Brazil25 Process of adaptation and implementation of MAF-TB with engagement of different relevant stakeholders (including civil society and TB affected community) in the Democratic Republic of Congo Dr Michel Kaswa, NTP Manager, Democratic Republic of Congo, and Mr Bertrand Kampoer, WHO Civil Society Task Force member Democratic Republic of Congo26 MAF-TB approach in the Russian Federation Prof. Irina Vasilyeva, Director, NTP, Russian Federation Russian Federation27 Pakistan’s experience in piloting MAF-TB at sub-national level (in Punjab and Badin) Dr Basharat Javed, Common Management Unit for AIDS, TB, and Malaria, Pakistan Pakistan28 Civil society and TB community engagement in MAF-TB Baseline assessment in 5 countries of Eastern Europe and Central Asia Ms Yuliia Kalancha, Executive Director, and Ms Mariia Chuprynska, Programme Manager, TB Europe Coalition Eastern Europe and Central Asia29 Social protection in time of COVID-19 The session was moderated by Dr Ernesto Jaramillo (WHO). The following key messages were highlighted as an introduction: 24 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/85011a95-bec9-461f-bc1a-3b06ed9e9b9c 25 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/c552f1b8-6908-4e9b-a32d-e23352fd7dfa 26 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/c7ed88e1-73e4-40c4-8b10-553e55b472f8 27 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/86133de0-3723-4a20-bc79-732a523462b0 28 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/7a00c765-994e-45ab-b2e8-1ed73a246e76 29 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/66d6ca79-8856-4ecf-b131-625f2ad2dfe3 8 • TB is not just a struggle against a single disease requiring medical interventions, but also a struggle to end poverty, inequality, unsafe housing, discrimination and stigma, and to extend social protection and universal health coverage. • Social protection is a collection of policies to provide insurance or social assistance to address social vulnerabilities faced by people affected by the disease. • Full implementation of all components of the MAF-TB framework could help to effectively address social protection at country level. • Collaboration with other UN agencies should also be considered in the context of MAF-TB. To facilitate discussion and sharing of information, the below listed country experiences and work carried out by the International Labour Organization in Kenya and the World Food Programme at a more global level was highlighted. Links to slides made available by speakers are captured in the below table. Table 4: Links to country experiences and work carried out by other agencies on social protection Focus of intervention Link to slides International Labour Organization in Kenya: Work on occupational promotion and prevention as well as social protection for people with TB (2017 – 2019) Dr Hellen Magutu, ILO Kenya Speaker did not present slides. TB response strategies in workplaces in Kenya and lessons learnt Dr. Wendy Nkirote, NTP, Kenya Kenya30 World Food Programme: A Food Security and Nutrition Lens to TB programming Mr Michael Smith, World Food Programme World Food Programme31 The First National TB Patient Cost Survey conducted in Viet Nam and its role in TB Social Protection Asso. Prof. Nguyen Binh Hoa, Vice Manager, NTP Viet Nam Viet Nam32 Azerbaijan’s experience in the provision of social and psychological supports for prisoners with TB Professor Hagigat Gadirova, NTP Manager, Azerbaijan and Dr. Rafail Mekhtiyev, Head, Medical Department of the Ministry of Justice, Azerbaijan Azerbaijan33 4. Pillar 3 – Intensified research and innovation and learning lessons from the COVID-19 response (Session 4) Session 4 consisted of the 2 segments. Part 1 was informative. Dr Birgitte Giersing (WHO) provided an update on WHO’s TB vaccine policy and research work. This included information on the TB vaccine pipeline, as well as the roadmap for new TB vaccines and ongoing work aimed at discussing needs (in terms of activities and data) – and their interdependencies – to facilitate accelerated global introduction of new TB vaccines. Link to slides presented by Dr Birgitte Giersing. 30 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/dedf7a15-f13c-4a60-8aac-c1c1ce33fba5 31 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/3d9f0dc3-61f9-4599-8063-e184c5604286 32 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/2e831e44-7d2d-4532-bdae-0f15d9cd7ef9 33 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/6aa44e3d-197f-40ff-b080-a7ab7058abb2 9 Part 2 of the session was interactive and thematically focused on operational research activities, including a spotlight on regional and country specific experiences, as summarized in the below table. A live, question and answer session was conducted in parallel to information shared by presenters. Table 5: Links to country and regional experiences on operational research Focus of intervention Link to slides Implementation research projects carried out in West and Central Africa through a reginal, phased, and collaborative approach Dr Corinne Merle, Scientist (Intervention Research), WHO/TDR West and Central Africa34 Key findings from Brazil’s first national survey of costs incurred by TB patients: The economic burden of families affected by TB in Brazil (2019 – 2021) Dr Ethel Maciel, Universidade Federal do Espírito Santo, Brazil Brazil35 European regional operational research activities on TB and drug-resistant TB Dr Askar Yedilbayev, TB Team Leader, WHO EUR European Region36 5. Looking ahead - Key Updates (Session 5) Session 5 was divided into 2 segments. Part 1 was an interactive session focused on preparations for the 2023 UNHLM on TB and the linked review of progress towards global TB targets. Part 2 and 3 were informative and aimed at creating awareness about the tools developed by WHO to facilitate the rapid uptake of WHO guidelines on TB - the WHO TB Knowledge Sharing Platform and the eTB Guidelines – and the upcoming release of new End TB Strategy operational guide, and the WHO End TB Forum. 2023 United Nations high-level meeting (UNHLM) on TB & review of progress made towards reaching global TB targets Dr Tereza Kasaeva provided an update on work streams leading up to the 2023 UNHLM on TB, including the development of an action oriented political declaration, agreed in advance by consensus through intergovernmental negotiations. The role of stakeholders in facilitating the preparation of this event was highlighted. Participants were also alerted to the UN General Assembly Interactive Civil Society Hearing, scheduled for mid- 2023. Link to slides presented by Dr Tereza Kasaeva.37 Subsequently, participants were invited to share with WHO their needs for support concerning (1) the upcoming high-level review of progress towards global TB targets; (2) the 2023 UNHLM political declaration; and (3) joint advocacy aimed at capitalizing on the UNHLM momentum. Responses are summarized below: • an advocacy package with key points and investment case to help reach and convince Minsters and Heads of State to invest in TB; • funding for community, participation, consultation, and shadow report; • sharing of country success stories; • identification and engagement of 3 champions from each WHO region in the planning team; • funding to facilitate attendance of low-income countries; • active engagement of all three levels of WHO; 34 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/63dc85c5-f9b2-49e1-8196-c5c37e6f3ff5 35 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/23e9e697-d38c-44c9-90cb-5257d867790d 36 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/ffb922b5-8b39-48e2-8d1c-4cc0d95b48d6 37 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/214d533f-f560-412c-9761-f12a9d45ed13 10 • joint advocacy activities to elevate TB to a priority intervention at country level (esp. in HBCs) given the context of the COVID-19 pandemic; and • inclusion of the perspective of youth and young advocates in the high-level meeting and work on the declaration. The WHO TB Knowledge Sharing Platform (“KSP”) Participants were briefed on the availability of the platform38 and mobile applications.39 Both provide a one stop shop for access to latest WHO TB Guidelines, modules of the WHO Operational Handbook, and training materials. Key features of the platform were highlighted as being quick links to resources, searching across all sections, access to eTB guidelines40 recommendation database, bookmark information, customize content, and logging into a personal space. Additional features accessible via the mobile application were also spotlighted, i.e. quick access to a recommendation summary, interactive algorithms, and user-defined dose calculators. The KSP will be further developed in 2022 with the launch of multiple language interfaces, new training modules and an application for offline use on desktops and laptops. Link to slides presented by Ms Karina Halle.41 Upcoming release of the End TB Strategy Operational Guide: “The Essentials” Updates to feature in the above-referenced document were confirmed as including: UNHLM commitments and targets, 10 priority recommendations from the report issued by the UN Secretary General; MAF-TB, new guidelines and policies, new tools including drugs, TB diagnostics, and innovations (such as digital technologies), new research and innovation strategy, more data and surveillance (including patient cost surveys), and information on the COVID-19 pandemic. Hyperlinks will be provided to facilitate quick access to WHO developed tools and information specific to the three pillars of the End TB Strategy. Link to slides presented by Ms Monica Dias.42 WHO End TB Forum Within this platform43 attention was drawn to existing networks: Mobilizing #Youth2EndTB, Public Private Mix (PPM) for TB care and prevention; MAF-TB, End TB platform for High Burden TB countries. 6. Closing In her closing remarks, Dr Tereza Kasaeva, recognized and thanked NTPs for their leadership, and also highlighted the need for continued and close engagement of the community, civil society, and partners to end TB. Dr Kasaeva further expressed her gratitude for the financial support from USAID and the Government of Japan. She further recognized and thanked participants for the wealth of strategic information shared with regards to the implementation of the 3 pillars of the End TB Strategy within the context of the COVID-19 pandemic from the national, regional and global level and discussion held. The need for further urgent and joint action to restore and scale-up the response to TB, mobilize additional domestic and international resources, and accelerate the development and uptake of new technologies and innovative integrated care approaches was stressed. The importance of giving equal standing to the implementation of the 3 pillars of the 38 Home | TB Knowledge Sharing (https://extranet.who.int/tbknowledge). 39 https://play.google.com/store/apps/details?id=com.whotbksp Or https://apps.apple.com/us/app/who-tb- guide/id1569546750 . 40 https://who.tuberculosis.recmap.org 41 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/77f7663e-93da-48ec-84ec-361c48a08490 42 https://global-tb-programme.hivebrite.com/topics/20775/media_center/file/ddf8e72a-6368-41a2-8185-ddac9084721b 43 https://global-tb-programme.hivebrite.com 11 End TB Strategy was also highlighted. Dr Kasaeva reflected on contributions already made by the TB community across the world in strengthen health systems and the need to further capitalize on the skill set of the TB community to build resilient health systems, capable of an effective response to airborne diseases and – by extension – TB. Dr Kasaeva closed the summit by stressing the need for innovative and joint action to reverse the impact of the pandemic, avert preventable deaths and put the world on track to end TB. 12 Annex 1: Agenda for the Summit’s AM and PM session 13 7th END TB STRATEGY SUMMIT of the Highest TB Burden Countries & Countries on the Global TB Watch List 7th Summit, Virtual 16–17 November 2021 9am to 12.30pm All times are CET Agenda The meeting language is English. Translation is offered into Russian. 14 Day 1: Tuesday, 16 November 09:00 – 12.30 CET 20 minutes OPENING: Welcome and review of meeting objectives and agenda 9.00 – 9.10 Welcome and introductions Dr Tereza Kasaeva, Director, WHO Global TB Programme (GTB), WHO 9.10 – 9.15 Opening remarks Dr Ren Minghui, Assistant Director- General for Universal Health Coverage/ Communicable and Noncommunicable Diseases (UCN*), WHO 9.15 – 9.20 Meeting objectives, overview of the agenda, meeting format Ms Karina Halle, GTB, WHO/GTB Dr Christian Gunneberg, WHO/GTB 1 hour 10 min SESSION 1: The impact of the COVID-19 Pandemic on reaching the Global TB Targets 9.20 – 9.40 High level perspectives and messages Dr Tereza Kasaeva, Director, WHO/GTB 9.40 – 10.00 Global TB Report 2021: Key findings and messages Dr Katherine Floyd, WHO/GTB 10.00 – 10.20 Partner Perspectives Dr Lucica Ditiu, Director, StopTB Partnership Dr Eliud Wandwalo, Head Tuberculosis, The Global Fund Dr YaDiul Mukadi, Medical Officer, USAID 10.20 – 10.30 Perspective from WHO Civil Society Task Force (CSTF) on the impact of COVID-19 on TB response efforts Ms Blessi Kumar, Civil Society Task Force member 10.30 – 10.40 VIRTUAL END TB SUMMIT SNAPSHOT & Icebreaker Activity coordinated by Ms Wang Yi WHO/GTB 15 1 hour 50 minutes SESSION 2 – Pillar 1 of the End TB Strategy Integrated people centered care and prevention in the time of COVID-19 Moderator: Ms Monica Dias, WHO/GTB 10.40 – 11.55 Spotlight panel Accelerating access to people-centered TB prevention and care in the face of the COVID-19 pandemic - Regional perspectives and country experiences Experience sharing by countries and partners via SLIDO on each key topic (Open text poll) WHO Eastern Mediterranean Region: - Regional perspective: Dr Martin van den Boom, Regional Advisor, WHO Eastern Mediterranean Region - Spotlight on comorbidities and vulnerable populations: Dr Basharat Javed, Common Management Unit for AIDS, TB, and Malaria, Pakistan WHO European Region: - Regional perspective: Dr Askar Yedilbayev, TB Team Leader, WHO European Region - Spotlight on TB prevention & screening: Dr Adenov Malik Moldabekovich, Director, National Scientific Center of Phthisiopulmonology, Kazakhstan - Spotlight on treatment: Dr Yana Terleieva, Head of TB Diagnosis and Treatment Coordination Department, Public Health Center of the MOH of Ukraine WHO South-East Asia Region: - Regional perspective: Dr Mukta Sharma, TB Regional Advisor, WHO South East Asia Region - Dr Sudarsan Mandal, Deputy Director General TB, NTP, India - Spotlight on community and civil society engagement: Dr Esty Febriani, Civil Society Task Force member, Indonesia WHO Western Pacific Region: - Regional perspective: Dr Tauhid Islam, TB Coordinator, WHO Western Pacific Region - Spotlight on TB diagnosis: Dr Anna Marie Celina Garfin, Medical Specialist IV, NTP manager, Philippines 16 11.55 – 12.25 Interactive Forum: Key priorities and innovations to enable rapid implementation of Pillar 1 of the End TB Strategy All: SLIDO 12.25 – 12.30 Wrap-up of Session Ms Monica Dias, WHO/GTB Day 2: Wednesday, 17 November 09:00 – 12.30 CET 1 hour Session 3: Pillar 2 of the End TB Strategy Bold policies and supportive systems to End TB in the context of the COVID-19 pandemic 9.00 – 9.30 Operationalization of multisectoral accountability framework – country experiences Moderators: Dr Sayohat Hasanova, WHO Dr Martin van den Boom, Regional Advisor, WHO Eastern Mediterranean Region Speakers: Prof. Irina Vasilyeva, Director, NTP, Russian Federation Dr Basharat Javed, Common Management Unit for AIDS, TB, and Malaria, Pakistan Ms Yuliia Kalancha, Executive Director, TB Europe Coalition Ms Mariia Chuprynska, Program Manager, TB Europe Coalition 9.30 – 10.00 How to leverage social protection in time of COVID-19 – spotlight on country experiences Moderator Dr Ernesto Jaramillo Speakers: Asso. Prof. Nguyen Binh Hoa, Vice Manager, NTP Viet Nam Dr Hagigat Gadirova, NTP Manager, Azerbaijan Dr. Rafail Mekhtiyev, Head, Medical Department of the Ministry of Justice, Azerbaijan 17 1 hour Session 4: End TB Strategy Pillar 3 – Intensified research and innovation, Learning lessons from the COVID-19 response Moderator: Dr Dennis Falzon, WHO 10.00 – 10:15 Update on WHO TB vaccine policy and research work Speaker: Dr Birgitte Giersing, Team Lead, Vaccine Platforms and Prioritization, WHO 10:15 – 11.00 Implementation of global strategy for TB research and innovation - spotlight on • European regional operational research activities on TB • Implementation research projects carried out in West Central Africa • Key findings from Brazil’s catastrophic cost survey Speakers: Dr Askar Yedilbayev, TB Team Leader, WHO European Region Dr Corinne Merle, Scientist (Intervention Research), WHO/TDR Dr Ethel Leonor Noia Maciel, Universidade Federal do Espírito Santo, Brazil 11.00 – 11.10 BREAK 1 hour 10 minutes Session 5: Looking ahead - Key Updates 11.10 – 12.00 Preparations for the 2023 UN High Level Meeting on TB and linked review Open Forum - Key asks from High Burden Countries Dr Tereza Kasaeva, Director, WHO/GTB Ms Monica Dias 12.00 – 12.05 Implementing the End TB Strategy: Essentials Ms Monica Dias, WHO/GTB 12.05 – 12.20 Knowledge Sharing Platform/Training materials on diagnostics, DR-TB and TB preventive treatment Ms Karina Halle, WHO/GTB 10 minutes Closing 12.20 – 12.30 Closing remarks Dr Tereza Kasaeva, Director, WHO Global TB Programme (GTB), WHO 18 7th END TB STRATEGY SUMMIT of the Highest TB Burden Countries & Countries on the Global TB Watch List 7th Summit, Virtual 16–17 November 2021 2pm to 5.30pm All times are CET Agenda The meeting language is English. Translation is offered into French, Spanish and Portuguese. 19 Day 1: Tuesday, 16 November 14:00 – 17.30 CET 20 minutes OPENING: Welcome and review of meeting objectives and agenda 14.00 – 14.10 Welcome and introductions Dr Tereza Kasaeva, Director, WHO Global TB Programme (GTB), WHO 14.10 – 14.15 Opening remarks Dr Ren Minghui, Assistant Director- General for Universal Health Coverage/ Communicable and Noncommunicable Diseases (UCN*), WHO 14.15 – 14.20 Meeting objectives, overview of the agenda, meeting format Ms Karina Halle, WHO/GTB Dr Christian Gunneberg, WHO/GTB 1 hour 10 min SESSION 1: The impact of the COVID-19 Pandemic on reaching the Global TB Targets 14.20 – 14.40 High level perspectives and messages Dr Tereza Kasaeva, Director, WHO/GTB 14.40 – 15.00 Global TB Report 2021: Key findings and messages Dr Katherine Floyd, WHO/GTB 15.00 – 15.20 Partner Perspectives Dr. Lucica Ditiu, Director, StopTB Partnership Dr Mohammed Yassin, Senior Advisor, Tuberculosis, The Global Fund Dr YaDiul Mukadi, Medical Officer, USAID 15.20 – 15.30 Perspective from WHO Civil Society Task Force (CSTF) on the impact of COVID-19 on TB response efforts Prof Harry Hausler, Civil Society Task Force member 15.30 – 15.40 VIRTUAL END TB SUMMIT SNAPSHOT & Icebreaker Activity coordinated by Ms Wang Yi WHO/GTB 20 1 hour 50 minutes SESSION 2 – Pillar 1 of the End TB Strategy Integrated people centered care and prevention in the time of COVID-19 Moderator: Ms Monica Dias, WHO/GTB 15.40 – 16.55 Spotlight panel Accelerating access to people-centered TB prevention and care in the face of the COVID-19 pandemic - Regional perspectives and country experiences Experience sharing by countries and partners via SLIDO on each key topic (Open text poll) WHO African Region: - Regional perspective: Dr André Ndongosieme, TB Regional Advisor a.i., WHO African Region - Spotlight on TB prevention & Screening: Dr Patrick Lungu, NTP Manager, Zambia - Spotlight on TB diagnosis: Dr Stavia Turyahabwe, Programme Manager, NTP Uganda - Spotlight on treatment: Dr Norbert Ndjeka, Director of DR-TB, National Department of Health, South Africa - Spotlight on public-private mix: Dr Chukwuma Anyaike, Director and National Coordinator, NTP, Nigeria - Spotlight on community and civil society engagement: Ms Evaline Kibuchi, WHO Civil Society Task Force member, Kenya WHO Region of the Americas: - Regional perspective: Dr Rafael Lopez Olarte, TB Regional Advisor, WHO Region of the Americas - Spotlight on comorbidities and vulnerable populations: Dr Julia Rosa María Rios Vidal, NTP manager, Peru 16.55 – 17.25 Interactive Forum: Key priorities and innovations to enable rapid implementation of Pillar 1 of the End TB Strategy All: SLIDO 17.25 – 17.30 Wrap-up of Session Ms Monica Dias, WHO/GTB 21 Day 2: Wednesday, 17 November 14:00 – 17.30 CET 1 hour Session 3: Pillar 2 of the End TB Strategy Bold policies and supportive systems to End TB in the context of the COVID-19 pandemic 14.00 – 14.30 Operationalization of multisectoral accountability framework – country experiences Moderators: Dr Sayohat Hasanova, WHO Dr Rafael Lopez Olarte, TB Regional Advisor, WHO Region of the Americas Speakers: Dr Tiemi Arakawa, NTP, Brazil Dr Michel Kaswa, NTP Manager, Democratic Republic of Congo Mr Bertrand Kampoer, Civil Society Task Force Member 14.30 – 15.00 How to leverage social protection in time of COVID-19 – spotlight on country experiences Moderator Dr Ernesto Jaramillo Speakers: Dr Hellen Magutu, ILO Kenya Dr. Wendy Nkirote, NTP, Kenya Mr Michael Smith, World Food Programme 1 hour Session 4: End TB Strategy Pillar 3 – Intensified research and innovation, Learning lessons from the COVID-19 response Moderator: Dr Dennis Falzon, WHO 15.00 – 15:15 Update on WHO TB vaccine policy and research work Speaker: Dr Birgitte Giersing, Team Lead, Vaccine Platforms and Prioritization, WHO 15:15 – 16.00 Implementation of global strategy for TB research and innovation - spotlight on • Implementation research projects carried out in West Central Africa • Key findings from Brazil’s catastrophic cost survey • European regional operational research activities on TB Speakers: Dr Corinne Merle, Scientist (Intervention Research), WHO/TDR Dr Ethel Leonor Noia Maciel, Universidade Federal do Espírito Santo, Brazil Dr Askar Yedilbayev, TB Team Leader, WHO European Region 16.00 – 16.10 BREAK 22 1 hour 10 minutes Session 5: Looking ahead - Key Updates 16.10 – 17.00 Preparations for the 2023 UN High Level Meeting on TB and linked review Open Forum - Key asks from High Burden Countries Dr Tereza Kasaeva, Director, WHO/GTB 17.00 – 17.05 Implementing the End TB Strategy: Essentials Ms Monica Dias, WHO/GTB 17.05 – 17.20 Knowledge Sharing Platform/Training materials on diagnostics, DR-TB and TB preventive treatment Ms Karina Halle, WHO/GTB 10 minutes Closing 17.20 – 17.30 Closing remarks Dr Tereza Kasaeva, Director, WHO/GTB 23 Annex 2: List of participants 24 7th END TB STRATEGY SUMMIT of the 30 Highest TB Burden Countries & Countries on the Global TB Watch List Virtual meeting 16-17 November 2021 List of participants National TB Programmes AFR Angola 1. Ambrosio Disadidi Director, National TB Programme, Ministry of Health Central African Republic 2. Hervé-Gildas Gando Chef de Service, Ministry of Health Congo 3. F. H. Okemba Okombi Coordinateur, Coordinateur, Programme national de lutte contre la tuberculose Democratic Republic of the Congo 4. Michel Kaswa Kayomo Coordinateur, Coordinateur, Programme national de lutte contre la tuberculose Ethiopia 5. Taye Letta NTP Manager, National TB Programme, Ministry of Health Gabon 6. Mahoumbou Jocelyn Coordinateur, Programme national de lutte contre la tuberculose Kenya 7. Waqo Ejersa NTP Manager, National Leprosy & TB Programme, Ministry of Public Health Lesotho 8. Bridget Maama Llang National TB Programme Manager, Ministry of Health 9. Thato Liname Mohale's Hoek 10. Lucy Tseka Berea district 11. Tlalane Makhebesela Mafeteng district 12. Mantahli Masia Molapo Leribe district 13. Puseletso Mofalali Mokhotlong district 14. Mabatho Molete Butha Buthe district 15. Joseph Tséhlo Thaba Tseka districts 16. Michael Mohlouoa Quthing District 17. Molupe Mokone Qacha's Nek district 18. Kholu Malefane Maseru district Liberia 19. Ernest Cholopray Programme Manager, National Leprosy & TB Control Program, Ministry of Health Mozambique 20. Benedita José Program Manager a.i., National TB Programme, Ministry of Health 21. Bachir Macuacua Technical Advisor, National TB Programme, Ministry of Health 25 Namibia 22. Ndahafa Aina Nandjebo National TB Programme Manager, Health Program Directorate of Special Programmes, Ministry of Health and Social Services Nigeria 23. Chukwuma Anyaike Director and National Coordinator, National TB and Leprosy Control Programme, Ministry of Health Sierra Leone 24. Alhassan Seisay acting Programme Manager, National TB, Leprosy Control Programme, Ministry of Health South Africa 25. Norbert Ndjeka Director of Drug-resistant Tuberculosis (DR-TB), National TB Programme, Department of Health Uganda 26. Stavia Turyahabwe Programme Manager Ag., Assistant Commissioner, National TB/Leprosy Programme United Republic of Tanzania 27. Riziki Kisonga Programme Manager, National Tuberculosis and Leprosy Programme, Ministry of Health Zambia 28. Patrick Lungu Manager, National TB Programme, Ministry of Health Zimbabwe 29. Charles Sandy, Manager, National TB Programme, Ministry of Health AMR Brazil 30. Fernanda Dockhorn Coordinator, Tuberculosis Programme, Department of Disease Surveillance, Ministry of Health and Family Welfare 31. Tiemi Arakawa Coordinator of the surveillance unit, Tuberculosis Programme, Department of Disease Surveillance, Ministry of Health and Family Welfare Peru 32. Julia Rosa Maria Ríos Vidal Executive Director, Programa Nacional de prevención y Control de Tuberculosis EMR Pakistan 33. Abdul Wali Khan Deputy National Coordinator, Tuberculosis National Control Programme Manager, Ministry of Health 34. Basharat Javed Tuberculosis National Control Programme Manager, Ministry of Health EUR Azerbaijan 35. Hagigat Gadirova Director of Scientific Research Centre of Lung Diseases 36. Rafail Mekhtiyev Head of Medical Department of the Ministry of Justice Belarus 37. Gennadz Hurevich Director, Republican Scientific-Research Center of Phthisiopulmonology 38. Alena Skrahina Deputy Director, Republican Scientific-Research Center of Phthisiopulmonology Kazakhstan 39. Malik Adenov Director of National Scientific Center of Phthisiopulmonology Kyrgyzstan 40. Madamin Karataev Director of National Center of Phthisiatry Republic of Moldova 41. Valentina Vilc Deputy Director of Republican Institute 26 Tajikistan 42. Asliddin Rajabzoda Director of Republican TB Center Ukraine 43. Yana Terleieva Head of TB Diagnosis and Treatment Coordination Department, Public Health Center of the MOH of Ukraine Uzbekistan 44. Nargiza Parpieva Director of Republican specialized scientific practical medical center of phthisiology and pulmonology, Ministry of Health, Republic of Uzbekistan Russian Federation 45. Irina Vasilyeva Chief TB Specialist, Director of RIPP, Ministry of Health SEAR Bangladesh 46. Khurshid Alam Director DGHS and Line Director TB - Leprosy & ASP India 47. Sudarsan Mandal Deputy Director General-TB and National TB Programme Manager, National TB Elimination Programme, Ministry of Health & Family Welfare Indonesia 48. Tiara Pakasi National TB Programme Manager, Directorate of Communicable Disease, Disease Prevention & Control, Ministry of Health Nepal 49. Bhim Singh Tinkari National TB Programme Manager, Director, National TB Centre, Ministry of Health & Population Thailand 50. Phalin Kamolwat Director, Bureau of Tuberculosis, Ministry of Health WPR Cambodia 51. Huot Chan Yuda Director of the National Center for TB and Leprosy Control, Ministry of Health 52. Tieng Sivanna Deputy Director of the National Center for TB and Leprosy Control, Ministry of Health 53. Khun Kim Eam Deputy Director of the National Center for TB and Leprosy Control, Ministry of Health 54. Pheng Sok Heng Deputy Director of the National Center for TB and Leprosy Control, Ministry of Health China (People's Republic of) 55. Zhao Yanlin Director of NCTB, China Mongolia 56. Erdenee Oyunchimeg Head of TB Surveillance and Research Department National Center for Communicable Diseases 57. Amarzaya Sarankhuu Officer in charge of HIV STI, Tuberculosis and Hepatitis prevention and control, Division of Communicable Diseases Papua New Guinea 58. Margaret Nasil Kal acting Program Manager, National TB Program, National Department of Health Philippines 59. Anna Marie Celina Garfin Medical Specialist IV and National TB Programme Manager, Department of Health Viet Nam 60. Nguyen Binh Hoa Manager, National TB Control Programme, Ministry of Health 27 Civil Society Task Force 61. Amir Khan Association for Social Development Pakistan 62. Aneeta Pasha Country Director, IRD Pakistan 63. Bertrand Kampoer Coordinator For Impacts in Social Health Cameroon 64. Blessi Kumar CEO Global Coalition of TB Activists India 65. Chamreun Sok Choub Executive Director, KHANA Cambodia 66. Evaline Kibuchi Kenya AIDS NGO Consortium (KANCO) Kenya 67. Esty Febriani TB Advisor Lembaga Kesehatan Nahdlatul Ulama Indonesia 68. Ezio Távora dos Santos Filho REDE-TB - Brazilian Network of Tuberculosis Research 69. Fatima Karmadwala TB affected community representative, UK 70. Harry Hausler Medical Director Project Integrate, TB Care Association Waterfront South Africa 71. Jamilya Ismoilova Independent Consultant/Advocate 72. Jeffry Acaba TB Advocat, APCASO Thailand 73. Nyan Win Phyo Coordinator, Health Technical, Monitorin and Evaluation World Vision Foundation of Thailand 74. Paran Winarni TB affected community representative PETA Indonesia 75. Roger Kamugasha Editor In Chief The Health Times Africa Limited Uganda 76. Tenzin Kunor Advocacy Coordinator,We are TB USA 77. Yuliya Chorna Executive Director TB Advocate Canada 78. Mazida Perseus IMUT 79. Budi Hermawan POP TB 28 Global Partners Bill and Melinda Gates Foundation 80. Guy Stallworthy Private Sector Lead The Global Fund to fight AIDS, TB and Malaria 81. Eliud Wandwalo Head of TB 82. Mohammed Yassin Senior Disease Advisor-TB 83. Celeste Gracia Edwards Disease Advisor, TB/HIV 84. Daisy Lekharu Disease Advisor, TB 85. Enos Masini Senior Disease Advisor-TB 86. Anna Scardigli Senior Disease Advisor-TB 87. Jamie Tonsing Senior Disease Advisor-TB 88. Melanie Kitongo Technical Analyst 89. Nnamdi Nwaneri Specialist - Impact and Evaluation 90. Grania Brigden Senior TB Advisor International Union Against Tuberculosis and Lung Disease (The Union) 91. Guy Marks President of The Union and a.i. Executive Director 92. Kobto Ghislain Koura Francophone Africa lead 93. Kuldeep Singh Sachdeva Director of The Union South East Asia office KNCV 92. Mustapha Gidado Executive Director 93. Agnes Gebhard Public Health Specialist, Technical Director 94. Emmy van der Grinten Manager Technical Division StopTB Partnership 95. Lucica Ditiu Executive Director 96. Sreenivas Nair 97. Andrei Mosneaga 98. Zaza Munez 99. Waqas Rabbani 100. Thandi Katlholo 101. Salama Mwatawala 102. Ekpeno Akpanowo ............Column Break.................. UNITAID 102. Draurio Barreira Senior Technical Manager 103. Eva Nathanson Manager, Programmes 104. Luca Occhini Team Lead, Programmes USAID 105. YaDiul Mukadi Medical Officer 29 Regional Partners AFR Africa CDC 106. Yenew Kebede Tebeja Head of Division of Laboratory Systems ASLM 107. Marguerite Massinga Loembe Senior Officer Laboratory Damien Foundation 108. Alberto Roggi Medical consultant Expertise France Initiative 5% 109. Veronica Noseda Head of operational research, L’Initiative 110. Jane Deuve Scientific advisor, L’Initiative FIND 111. Heidi Albert Head of FIND office, South Africa SRL Benin 112. Dissou Affolabi Head of the SRL SRL Uganda 113. Moses Joloba Head of the SRL ILO 114. Hellen Magutu National Program Coordinator, Kenya AMR Partners in Health (Peru) 115. Leonid Lecca Executive Director, Socios En Salud | Partners In Health Peru Parliamentary caucus 116. Rachel Sterman Americas & Lusophone Regional Coordinator, Global TB Caucus Regional Civil Society Network 117. Alberto Colorado Americas TB Coalition Coordinator, Patient Advocate/International Public Health Consultant Asociación de Personas Afectadas por Tuberculosis – ASPAT 118. Melecio Mayta Director Ejecutivo Internacional The Global Fund 119. Giulia Perrone Regional Manager - Latin America and Caribbean Team USAID 120. Ken Castro TB focal point 121. Charlotte Colvin TB focal point Damian Foundation 122. Nimer Ortuño-Gutierrez medical Advisor Universidade Federal do Espirito Santo (UFES) 123. Ethel Leonor Maciel Professor of Epidemiology EMR IOM 124. Saiful Quayyum Regional Technical Officer (Public Health) USAID 125. Thomas Chiang Senior Tuberculosis Technical Advisor 30 Global Fund 126. Urban Weber Head of High Impact Asia FPM Pakistan 127. Izaskun Gaviria Fund Portfolio Manager EUR MSF 128. Cathy Hewison Medical Advisor Partners in Health (PIH) 129. Michael Rich Associate Physician 130. Yerkebulan Algozhin Kazakhstan Country Director USAID missions in Central Asia, Uzbekistan, Tajikistan 131. Sholpan Makhmudova Agreement Officer’s Representative 132. Arman Toktabayanov Regional Tuberculosis Advisor 133. Flora Salikhova Project Management Specialist - Uzbekistan 134. Lola Yuldasheva Agreement Officer’s Representative 135. Nargiza Metyakubova GFATM – EECA group 136. Dumitru Laticevschi Regional Manager Eastern Europe and Central Asia Team TB Europe Coalition 137. Yuliia Kalancha Executive Director 138. Mariia Chuprynska Programme Manager SEAR LHL International 139. Mona Drage Managing Director WPR rGLC 140. Mamel Quelapio rGLC chair TAG 141. Mario Raviglione TAG chair Queensland Mycobacterium Reference Laboratory (QMRL) 142. Christopher Coulter Director Research Institute of Tuberculosis, Tokyo (RIT) 143. Seiya Kato Director 144. Satoshi Mitarai Korean Institute of Tuberculosis - KIT Korea 145. Kyungjong Kim Research Scientist 146. Whijun Kim Beijing Chest Hospital, Capital Medical University, Beijing 147. Gao Jing Tao Deputy Director Marie Bashir Institute for Infectious Diseases and Biosecurity 148. Ben Marais Deputy Director Adelaide (SA Pathology (RAH)) 149. Ivan Bastian Clinical Director Hospital Authority, Department of Health, Hong Kong 150. Dominic Tsang Ngai-chong Chief infection control officer 31 WHO Country Offices AFR Angola 151. Nzuzi Katondi National Professional Officer Central African Republic 152. Aristide Désiré Komangoya Nzonzo National Professional Officer /ATM, Hep Democratic Republic of the Congo 153. Nicolas Nkiere Masheni National Professional Officer TUB Ethiopia 154. Abebe Eshetu Abeje National Professional Officer /TB  Community DOTS 155. Esther Aceng MO/ATM 156. Fekadeselassie Mikru Asfaw National Professional Officer /TB 157. Ismael Hassen Endris National Professional Officer 158. Amanu Gisso Enki National Professional Officer /TB 159.Endale Berta Belachew National Professional Officer 160.Addisalem Yilma Tefera Monitoring & Evaluat Officer 161. Eshetu Kebede National Professional Officer 162. Seblewongel Abate Nigussie HIV Programme Coordinator 163. Ghion Tiriste HIV Treatment and TB prevention Focal point 164. Yadete Zenebech Wake National Professional Officer HIV/TB- Sub national level 165.Elleni Seyoum HIV Strategic information Gabon 166. Ghislaine Nkone Asseko National Professional Officer ATM Kenya 167. Eunice Omesa Medical Officer TB Lesotho 168. Susan Zimba Tembo Medical Officer /HIV & TB Liberia 169. Peter Clement Technical Officer/Focal Point HIV/AIDS/TB/MAL Mozambique 170. Nurbai Calu National Professional Officer /TB/HIV Namibia 171. Mary Brantuo Medical Officer DPC 172. Aina Erastus IPC SSA Nigeria 173. Ayodele Awe National Professional Officer /TUB 174. Philip Patrobas Dashi National Professional Officer /TUB, Global Fund Sierra Leone 175. Kassa Ketema Medical Officer /TB South Africa 176. Nkateko Mkhondo Medical Officer /TB South Africa MCAT 177. Fabian Ndezanko Medical Officer, HIV/TB/Hep Uganda 178. Simon Walusimbi National Professional Officer /TB United Republic of Tanzania 179. Christine Musanhu National Professional Officer /TB 32 Zambia 180. Lastone Chitembo National Professional Officer /HIV/TB Zimbabwe 181. Mkhokheli Ngwenya National Professional Officer AMR Argentina 182. Mario Masana Consultant Barbados 183. Prabhjot Singh Belize 184. Edwin Bolastig HSS Advisor Bolivia 185. Alfonso Tenorio TB focal point Brazil 186. Joel Keravec National Professional Officer 187. Miguel Angel Aragón TB focal point Colombia 188. Ingrid Garcia Costa Rica 189. Wilmer Marquiño Asesor en Vigilancia de la Salud, Prevención y Control de Enfermedades 190. Anna Jimenez Consultora Enfermedades Transmisibles Dominican Republic 191. Olivia Brathwaite TB focal point 192. Mary Esther Mercedes Fernández NPC/OPS El Salvador 193. Elizabeth Rodriguez Consultora en VIH-ITS-HV y TB Mexico 194. Edmundo Morales Galindo Consultor Nacional en Enfermedades Transmisbles Paraguay 195. Beatriz Cohenca TB focal point Suriname 196. Oscar Mesones Lapouble Technical Officer EMR Afghanistan 197. Muhammad Akhtar Programme Manager 198. Muhammad Reza Aloudal National Professional Officer Djibouti 199. Fatouma Salem National Professional Officer Egypt 200. Alaa Hashish National Professional Officer 188. Nahla Gamal El Din Consultant Iraq 201. Adnan Khamasi Public Health Officer Iran 202. Omid Zamani Consultant Libya 203. Santosha Kelamane Technical Officer 204. Mohamed Mabrok Abukalish National Professional Officer Jordan 205. Ala’a Sheikh National Professional Officer Palestine 206. Randa Abu Rabe National Professional Officer 33 Pakistan 207. Muhammad Aamir Safdar Consultant Somalia 208. Iraneus Sindani Medical Officer/TB Sudan 209. Mai El Tigany Mohammed National Professional Officer Syria 210. Ziad Aljarad National Professional Officer 211. Dr Hania Husseiny National Professional Officer Yemen 212. Najib Thabit National Professional Officer EUR Azerbaijan 213. Javahir Suleymanova National Professional Officer 214. Elturan Ismalyilov National Professional Officer Belarus 215. Viacheslav Grankov National Professional Officer Kazakhstan 216. Caroline Clarinval WHO Representative Kyrgyzstan 217. Nazira Artykova WHO Representative Republic of Moldova 218. Alexandru Voloc National Professional Officer Russian Federation 219. Aleksandr Goliusov National Professional Officer 220. Saltanat Yegeubayeva Medical Officer, TB, HIV, Hepatitis Tajikistan 221. Abdulakhad Safarov National Professional Officer Ukraine 222. Georgii Dymov National Professional Officer 223. Martin Donoghoe Medical Officer, TB, HIV, Hepatitis Uzbekistan 224. Jamshid Gadoev National Professional Officer /TB SEAR Bangladesh 225. Mya Sapal Ngon Medical Officer /Communicable Diseases 226. Arefin Saki National Professional Officer /TB Bhutan 227. Sunam Wangedi Democratic People's Republic of Korea 228. Kamar Rezwan Technical Officer – Project Manager India 229. Malik Parmar National Professional Officer /DR-TB 230. Kirankumar Rade National Professional Officer /TB Epidemiologist 231. Ranjani Ramachandran Coordination role for TB Activities 232. Alexandra Vokaty Team Leader, Communicable Diseases Indonesia 233. Shalala Ahmadova Technical Officer /ETB 234. Maria Regina Christian National Professional Officer (TB/Leprosy/Buruli Ulcer) 235. Setiawan Jati Laksono National Professional Officer /TB 236. Benjamin Sihombing National Professional Officer /TB 34 Maldives 237. Faiha Ibrahim National Professional Officer – EHA Myanmar 238. Aung Thu Senior NTO (HRD, Operational Research, Laboratory) 239. Sushil Dev Pant Medical Officer 240. Khine su National Professional Officer (Active Case Detection, CBTBC) 241. Ye Win Thein National Technical Officer (WHO, TB) 242. Aye Thida National Professional Officer 243. Kyaw Ko Ko Win National Professional Officer Nepal 244. Khin Pa Pa Naing Technical Officer 245. Ashish Shrestha National Professional Officer /TB Sri Lanka 246. Mizaia Cader National Professional Officer 247. Navaratnasingam Janakan National Professional Officer Thailand 248. Deyer Gopinath Medical Officer /TB/HIV 249. Richard Brown DR-TB and AMR Timor Leste 250. Debashish Kundu Technical Officer /CDS WPR Cambodia 251. Serongkea Deng National Professional Officer China (People's Republic of) 252. Zhongdan Chen National Professional Officer -TB,HIV, Hepatitis Lao People's Democratic Republic 253. Vilath Seevisay Technical Officer Malaysia 254. Karina Razali Consultant Mongolia 255. Anuzaya Purevdagva National Professional Officer Pacific Island Countries 256. Yadav Subhash Medical Officer (Tub) Papua New Guinea 257. Narantuya Jadambaa Medical Officer - Communicable Diseases 258. Anup Gurung Team Leader - Communicable Diseases Philippines 259. Rajendra-Prasad Hubraj Yadav Medical Officer /TB 260. Thomas Dale Hiatt Medical Officer Solomon Islands 261. Lanique Pitasua Consultant Viet Nam 262. Satoko Otsu Team Leader 263. Quang Hieu Vu National Professional Officer/TB 35 WHO Regional Offices AFRO 264. Jean Louis Abuena rGLC focal point 265. Jean De Dieu Iragena Technical Officer Lab 266. Hugues Lago Coordinator, HIV, Tuberculosis and Hepatitis255. 267. Andre Ndongosieme Regional Adviser a.i., TB 268. Michel Gasana Medical Officer /DR-TB and rGLC Focal Point AMRO 269. Rafael Lopez Olarte Regional Advisor, TB 270. Ernesto Montoro Cardoso Specialist, Tuberculosis Lab. Coordinator HIV, Hepatitis, Tuberculosis & Sexually Transmitted Infections Unit (CDE/HT) 271. Pedro Avedillo Specialist, Tuberculosis Prevention and Control HIV, Hepatitis, Tuberculosis & Sexually Transmitted Infections Unit (CDE/HT) 272. Rubén Mayorga Unit Chief, HIV, Hepatitis, Tuberculosis and Sexually Transmitted Infections - HT Unit EMRO 273. Martin van den Boom Regional Advisor TB 274. Kenza Bennani Medical Officer,TB EURO 275. Askar Yedilbayev TB Team Leader, Joint Tuberculosis, HIV/AIDS & Hepatitis Programme (JTH) 276. Andrei Dadu Medical Officer TB 277. Soudeh Eshani Technical Officer TB 278. Ogtay Gozalov Medical Officer TB 279. Giorgi Kuchukhidze Epidemiologist/SRM 280. Stela Bivol Strategic Advisor (Infectious Diseases) SEARO 281. Mukta Sharma Regional Adviser TB/HIV/STI/Hep 282. Partha Pratim Mandal Medical Officer /TB 283. Vineet Bhatia Medical Officer /MDR-TB WPRO 284. Tauhid Islam Coordinator, End TB and Leprosy Elimination (ETB) 285. Fukushi Morishita Technical Officer /ETB 286. Kalpesh Rahevar Medical Officer /ETB 287. Kyung Oh Technical Officer /ETB 36 WHO Headquarters 288. Ren Minghui Assistant Director-General/UCN 289. Tereza Kasaeva Director, GTB 290. Michael McCullough Unit Head, Planning, Analysis & Risk Management 291. Hannah Monica Dias Cross-cutting Specialist, WHO Flagship Initiative, PPM & TB Elimination 292. Karina Halle Cross-cutting Specialist, Enhanced TB Collaboration for Country Impact in high TB burden countries 293. Corinne Merle Scientist 294. Birgitte Giersing Team Lead, Vaccine Platforms and Prioritization 295. Farai Mavhunga Unit Head, Vulnerable Populations, Communities &Comorbidities 296. Ernesto Jaramillo Medical Officer 297. Matteo Zignol Unit Head a.i., TB Prevention, Diagnosis, Treatment, Care & Innovation (PCI) 298. Saskia Den Boon Technical Officer 299. Dennis Falzon Team Lead, TB Prevention, Research & Innovations 300. Nebiat Gebreselassie Technical Officer 301. Medea Gegia Technical Officer 302. Lice Gonzalez-Angulo Technical Officer 303. Nazir Ismail Team Lead, TB Screening and Diagnosis 304. Avinash Kanchar Medical Officer 305. Alexei Korobitsyn Technical Officer 306. Tiziana Masini Technical Officer 307. Cecily Miller Technical Officer 308. Fuad Mirzayev Team Lead, TB Treatment 309. Carl-Michael Nathanson Technical Officer 310. Linh Nhat Nguyen Medical Officer 311. Anna Stukalova Technical Officer 312. Kerri Viney Scientist 313. Samuel Schumacher Scientist 314. Katherine Floyd Unit Head, TB Monitoring, Evaluation & Strategic Information 315. Marie-Christine Bartens JPO 316. Anna Dean Technical Officer 317. Ines Garcia Baena Technical Officer 318. Philippe Glaziou Team Lead, Global Monitoring Estimates & Projections 319. Marek Lalli Technical Officer 320. Irwin Law Technical Officer 321. Nobuyuki Nishikiori Medical Officer 322. Charalampos Sismanidis Team Lead, TB Surveillance & Epidemiological Surveys 323. Hazim Timimi Data Manager 324. Annabel Baddeley Technical Officer 325. Rachel Beanland Consultant 326. Annemieke Brands Technical Officer 327. Christian Gunneberg Technical Officer 37 328. Soleil Labelle Technical Officer 329. Anne-Laure Lameyre Programme Officer 330. Sayohat Hasanova Technical Officer 331. Liana Oganezova Technical Officer 332. Cicilia Parwati Technical Officer 333. Lana Syed Technical Officer 334. Sabine Verkuijl Medical Officer 335. Yi Wang Consultant 336. Michael Tabiszewski Assistant to Team